Exploring the Impact of Selenium Supplementation on Nutritional, Inflammatory, and Cardiac Function in Chronic Heart Failure Patients: A Novel Approach to Managing Deficiency.
- 2025-07-16
- Cardiovascular toxicology 25(10)
- Ladi Kou
- Fandong Meng
- Guotao Fu
- Rongqiang Zhang
- PubMed: 40668353
- DOI: 10.1007/s12012-025-10041-3
Study Design
- Type
- Meta-Analysis
- Sample size
- n = 191
- Population
- 191 CHF patients
- Methods
- Measuring blood Se via 2,3-diaminonaphthalene fluorometry; systematic review of randomized trials on Se supplementation for CHF
This study investigated blood selenium (Se) levels in chronic heart failure (CHF) patients and their correlation with cardiac function, followed by a meta-analysis of Se supplementation efficacy. We enrolled 191 CHF patients, measuring blood Se via 2,3-diaminonaphthalene fluorometry. Data were analyzed using SPSS 25.0 and GraphPad Prism 8.0. A systematic review of randomized trials on Se supplementation for CHF was conducted (RevMan 5.3 and Stata 16.0). CHF patients exhibited significantly lower blood Se (P2.5-P97.5: 55.12-81.38 μg/L; median: 67.04 μg/L) versus healthy controls. Lower Se levels correlated with obesity (P = 0.001), rural residence (P = 0.009), hypertension (P = 0.038), and advanced cardiac dysfunction (class III/IV vs. I/II, P = 0.002). Se inversely correlated with CRP (r = - 0.22, P = 0.026). Meta-analysis revealed that Se supplementation reduced systolic blood pressure (P = 0.04) but increased LVESV (SMD = 0.21, P = 0.04). CHF patients frequently exhibit Se deficiency, linked to BMI, cardiac function, and inflammation. Hypertension and low Se may exacerbate cardiac dysfunction, while controlled Se supplementation could improve outcomes.
Research Insights
Meta-analysis revealed that Se supplementation reduced systolic blood pressure (P = 0.04)
- Effect
- Beneficial
- Effect size
- Small